Pacer U.S. Large Cap [COWG] vs Merck & Co [MRK] Detailed Stock Comparison
Pacer U.S. Large Cap
NASDAQ
Loading...
Merck & Co
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Pacer U.S. Large Cap wins in 6 metrics, Merck & Co wins in 7 metrics, with 0 ties. Merck & Co appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Pacer U.S. Large Cap | Merck & Co | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 29.68 | 12.31 | Merck & Co |
| Price-to-Book Ratio | N/A | 4.16 | N/A |
| Debt-to-Equity Ratio | 0.32 | 71.99 | Pacer U.S. Large Cap |
| PEG Ratio | -0.01 | 8.50 | Pacer U.S. Large Cap |
| EV/EBITDA | 49.91 | 7.71 | Merck & Co |
| Profit Margin (TTM) | 53.40% | 25.79% | Pacer U.S. Large Cap |
| Operating Margin (TTM) | N/A | 36.61% | N/A |
| EBITDA Margin (TTM) | N/A | 36.61% | N/A |
| Return on Equity | 43.83% | 36.91% | Pacer U.S. Large Cap |
| Return on Assets (TTM) | 16.34% | 14.62% | Pacer U.S. Large Cap |
| Free Cash Flow (TTM) | N/A | $18.10B | N/A |
| Dividend Yield | N/A | 3.01% | N/A |
| 1-Year Return | 33.19% | -30.65% | Pacer U.S. Large Cap |
| Price-to-Sales Ratio (TTM) | 6.79 | 3.15 | Merck & Co |
| Enterprise Value | $11.11B | $224.78B | Merck & Co |
| EV/Revenue Ratio | 6.76 | 3.53 | Merck & Co |
| Gross Profit Margin (TTM) | N/A | 77.98% | N/A |
| Revenue per Share (TTM) | $5 | $25 | Merck & Co |
| Earnings per Share (Diluted) | $0.37 | $6.49 | Merck & Co |
| Beta (Stock Volatility) | N/A | 0.39 | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Pacer U.S. Large Cap vs Merck & Co Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Pacer U.S. Large Cap | 0.29% | 0.17% | -0.79% | 7.41% | -0.06% | 8.24% |
| Merck & Co | 0.45% | 2.88% | -0.66% | 1.58% | -7.92% | -18.96% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Pacer U.S. Large Cap | 33.19% | 553.27% | 446.09% | 437.69% | 487.39% | 487.39% |
| Merck & Co | -30.65% | -12.72% | -0.28% | 40.68% | 138.06% | 172.71% |
Performance & Financial Health Analysis: Pacer U.S. Large Cap vs Merck & Co
| Metric | COWG | MRK |
|---|---|---|
| Market Information | ||
| Market Cap | $11.16B | $200.53B |
| Market Cap Category | Large cap | Mega cap |
| 10 Day Avg. Volume | 689,314 | 13,904,610 |
| 90 Day Avg. Volume | 771,611 | 15,207,197 |
| Last Close | $35.05 | $80.73 |
| 52 Week Range | $25.30 - $35.87 | $73.31 - $120.30 |
| % from 52W High | -2.29% | -32.89% |
| All-Time High | $35.87 (Feb 17, 2025) | $134.63 (Jun 24, 2024) |
| % from All-Time High | -2.29% | -40.04% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | -0.02% |
| Quarterly Earnings Growth | N/A | -0.19% |
| Financial Health | ||
| Profit Margin (TTM) | 0.53% | 0.26% |
| Operating Margin (TTM) | N/A | 0.37% |
| Return on Equity (TTM) | 0.44% | 0.37% |
| Debt to Equity (MRQ) | 0.32 | 71.99 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | N/A | $19.21 |
| Cash per Share (MRQ) | N/A | $3.68 |
| Operating Cash Flow (TTM) | $60.24M | $22.75B |
| Levered Free Cash Flow (TTM) | $118.36M | $17.12B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 3.01% |
| Last 12-Month Dividend | $0.00 | $2.39 |
Valuation & Enterprise Metrics Analysis: Pacer U.S. Large Cap vs Merck & Co
| Metric | COWG | MRK |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 29.68 | 12.31 |
| Forward P/E | N/A | 8.50 |
| PEG Ratio | -0.01 | 8.50 |
| Price to Sales (TTM) | 6.79 | 3.15 |
| Price to Book (MRQ) | N/A | 4.16 |
| Market Capitalization | ||
| Market Capitalization | $11.16B | $200.53B |
| Enterprise Value | $11.11B | $224.78B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 6.76 | 3.53 |
| Enterprise to EBITDA | 49.91 | 7.71 |
| Risk & Other Metrics | ||
| Beta | N/A | 0.39 |
| Book Value per Share (MRQ) | N/A | $19.21 |
Financial Statements Comparison: Pacer U.S. Large Cap vs Merck & Co
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | COWG | MRK |
|---|---|---|
| Revenue/Sales | N/A | $15.81B |
| Cost of Goods Sold | N/A | $3.56B |
| Gross Profit | N/A | $12.25B |
| Research & Development | N/A | $4.05B |
| Operating Income (EBIT) | N/A | $5.55B |
| EBITDA | N/A | $6.96B |
| Pre-Tax Income | N/A | $5.00B |
| Income Tax | N/A | $571.00M |
| Net Income (Profit) | N/A | $4.43B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | COWG | MRK |
|---|---|---|
| Cash & Equivalents | N/A | $8.63B |
| Total Current Assets | N/A | $35.50B |
| Total Current Liabilities | N/A | $25.17B |
| Long-Term Debt | N/A | $33.48B |
| Total Shareholders Equity | N/A | $48.40B |
| Retained Earnings | N/A | $66.10B |
| Property, Plant & Equipment | N/A | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | COWG | MRK |
|---|---|---|
| Operating Cash Flow | N/A | $6.30B |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | $1.17B |
| Debt Repayment | N/A | $-2.50B |
| Common Stock Repurchase | N/A | $-1.16B |
Short Interest & Institutional Ownership Analysis
| Metric | COWG | MRK |
|---|---|---|
| Shares Short | N/A | 28.77M |
| Short Ratio | N/A | 1.61 |
| Short % of Float | N/A | 0.01% |
| Average Daily Volume (10 Day) | 689,314 | 13,904,610 |
| Average Daily Volume (90 Day) | 771,611 | 15,207,197 |
| Shares Outstanding | 318.24M | 2.53B |
| Float Shares | N/A | 2.51B |
| % Held by Insiders | N/A | 0.00% |
| % Held by Institutions | N/A | 0.81% |
Dividend Analysis & Yield Comparison: Pacer U.S. Large Cap vs Merck & Co
| Metric | COWG | MRK |
|---|---|---|
| Last 12-Month Dividend | $0.00 | $2.39 |
| Last 12-Month Dividend Yield | N/A | 3.01% |
| 3-Year Avg Annual Dividend | $0.12 | $2.77 |
| 3-Year Avg Dividend Yield | 1.36% | 0.71% |
| 3-Year Total Dividends | $0.37 | $8.31 |
| Ex-Dividend Date | Dec 27, 2023 | Mar 17, 2025 |